Daikenchuto attenuates visceral pain and suppresses eosinophil infiltration in inflammatory bowel disease in murine models.

Researchers investigated whether Daikenchuto (DKT), a traditional Japanese herbal formula, could help with abdominal pain and inflammation in inflammatory bowel disease (IBD). IBD includes ulcerative colitis and Crohn's disease, conditions that cause chronic intestinal inflammation and persistent abdominal pain. The study used rat models of both types of IBD, comparing DKT to 5-aminosalicylic acid (5-ASA), a standard medication for IBD. Rats received DKT or 5-ASA orally once daily for five days after colitis was induced. Researchers measured pain responses using colorectal distention tests and evaluated inflammation through various markers including immune cell counts and tissue damage scores. The results showed that DKT significantly reduced visceral pain responses in both IBD models, while 5-ASA did not affect pain levels. Both DKT and 5-ASA reduced eosinophil infiltration, a type of inflammatory immune cell, in the intestinal tissue. Interestingly, the anti-inflammatory mechanisms of DKT appeared to differ from those of conventional medication. These findings suggest that DKT may be particularly beneficial for managing abdominal pain in IBD patients, and its unique mechanism could complement conventional treatments. The study supports the potential for combining traditional herbal formulas with standard medical care for better outcomes. While this research was conducted in animal models and human studies are needed, it provides scientific backing for traditional herbal approaches to digestive disorders. If you're considering acupuncture or traditional medicine for digestive issues, consult with a qualified, licensed practitioner who can evaluate your individual needs.

This preclinical study evaluated Daikenchuto's (DKT) efficacy in murine IBD models using Sprague-Dawley rats administered 4% DSS or TNBS to induce ulcerative colitis and Crohn's disease phenotypes, respectively. Treatment consisted of oral DKT or 5-ASA once daily from days 3-7 post-induction. Primary outcomes included visceromotor response (VMR) to colorectal distention and inflammatory markers (histological scoring, leukocyte infiltration, MPO activity, eosinophil counts). DKT significantly suppressed VMR in both DSS and TNBS models, while 5-ASA showed no analgesic effect. Both treatments reduced eosinophil infiltration in both models. MPO activity was suppressed by 5-ASA in DSS-treated rats only, while DKT showed no significant MPO reduction in either model. Clinical implications suggest DKT's analgesic mechanism operates independently of traditional anti-inflammatory pathways, targeting eosinophil-mediated inflammation specifically. The distinct mechanisms between DKT and 5-ASA support potential synergistic combination therapy. DKT may offer particular benefit for visceral hypersensitivity management in IBD patients where conventional therapies inadequately address pain symptoms.